Cerebral Imaging in Patients with COVID-19 and Neurological Symptoms: First Experience from two University Hospitals in Northern Germany

Zerebrale Bildgebung bei Patienten mit COVID-19 und neurologischer Symptomatik: Erste Erfahrung aus 2 norddeutschen Universitätskrankenhäusern

Authors
Ulf Jensen-Kondering1, Alexander Neumann2, Nils G. Margraf3, Felix Gövert3, Norbert Brüggemann4, Domagoj Schunk5, Thomas Bahmer6, Peter Schramm2, Stefan Schreiber6, Olav Jansen1

Affiliations
1 Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
2 Institute of Neuroradiology, University Hospital Schleswig-Holstein, Campus Lübeck, Germany
3 Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
4 Department of Neurology, University Hospital Schleswig-Holstein, Campus Lübeck, Germany
5 Emergency Department, University Hospital Schleswig-Holstein, Campus Kiel, Germany
6 Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Germany

Key words
brain, CNS, CT, infection, MR imaging

ABSTRACT

Purpose To describe findings on cerebral imaging in patients with COVID-19 and neurological symptoms at two German university hospitals.

Materials and Methods Patients with COVID-19 and neurological symptoms and cerebral imaging (CT or MRI) were included. A chart review regarding neurological symptoms, COVID-19 and imaging findings was conducted.

Results 12 patients (4 females, age 68 ± 12 years) could be included. Three patients had acute findings. Two patients had acute and subacute cerebral ischemia, one patient had additional intracranial hemorrhages and presumed central pontine myelinolysis. One patient had presumed COVID-19-associated pansinusitis.

Conclusion Findings on cerebral imaging in patients with COVID-19 are uncommon and nonspecific. However, cerebral ischemia is regularly encountered and patients should be evaluated for stroke symptoms.

Key Points:
▪ Approx. 20 % of patients with COVID-19 develop neurological symptoms.
▪ Findings on cerebral imaging in patients with COVID-19 are heterogeneous and nonspecific.
▪ The most common findings are cerebral ischemia and hemorrhages.

Citation Format

ZUSAMMENFASSUNG


Introduction

In December 2019, the first cases of pneumonia caused by a novel coronavirus (SARS-CoV2) were identified in Wuhan/China. The virus has since spread around the globe. The disease caused by SARS-CoV2, known as COVID-19, is typically characterized by a respiratory infection with cough and fever. However, other organ systems can also be affected at an early stage in some cases [1, 2]. According to an initial large retrospective analysis from Wuhan, approximately one third (36.4 %) of COVID-19 patients exhibit neurological manifestations [3]. The neuroinvasive potential of coronaviruses is already known. Neurological symptoms were able to be observed in SARS-CoV1 and MERS-CoV patients [4, 5]. At the end of June 2020, 193,243 cases in Germany and 3146 (108.6 per 100,000 inhabitants were reported in Schleswig-Holstein) (https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.html, as of 6/27/2020). In total, 68 patients had been hospitalized at both sites of the University Hospital of Schleswig-Holstein. We report on our first experience with cerebral imaging in COVID-19 patients with neurological symptoms.

Materials and Methods

All patients infected with SARS-CoV2 who underwent clinically indicated cerebral imaging were retrospectively included. Imaging findings were evaluated with respect to primary and secondary findings. The following were categorized as primary findings: acute pathologies that were the presumably cause of symptoms or presumably occurred during the infection or as a result of the infection. All pathological findings classified as preexisting were considered secondary findings. In addition, demographic data and clinical information regarding SARS-CoV2 infection were recorded.

Results

12 patients (4 women, 8 men, average age 68 ± 12 years) were able to be included (Table 1a). Two of the patients were examined after the infection had resolved. Three COVID-19 cases were mild, five were moderate, and four were severe (mild: no hospitalization, hospitalization without oxygen supply, moderate: oxygen supply, severe: intensive care). MRI examination was performed in two patients, CT examination in seven patients (including additional CT angiography in one case), and three additional patients underwent both CT and MRI. All MRI examinations were performed with IV contrast agent.

In one severe case of COVID-19, a brain stem lesion was detected and classified as presumed central pontine myelinolysis (Fig. 1). Two patients had acute and subacute cerebral ischemia (Fig. 2). One patient additionally had a combination of subarachnoid and parenchymal hemorrhages (Fig. 3). One patient had presumed COVID-19-associated sinusitis based on headache, imaging finding, and a positive PCR for SARS-CoV2 from a nasal swab (Fig. 4). None of the patients had acute inflammatory intracranial changes. No acute findings could be identified on imaging in the remaining patients. The most common secondary findings were preexisting microangiopathic white matter damage (n = 4) and old embolic and microangiopathic stroke (n = 2). The neurological symptoms occurred with the start of the other symptoms in six patients, over the course of hospitalization in four cases, and weeks later in two patients. Eight patients experienced complete resolution of their neurological symptoms, one patient was discharged in soporose state, and three patients died (Table 1b).

Discussion

Initial imaging results in a series of 58 patients with severe cases of COVID-19 were published by Helms et al. [6]. Meningeal contrast enhancement was seen in 8 of 13 patients (62 %) and cerebral ischemia in 3 patients (23 %).

Kandemili et al. report on patients with severe cases of COVID-19 in Turkey [7]. Cortical signal changes in FLAIR weighting accompanied by cortical diffusion impairment, leptomeningeal enhancement, or cortical blooming artifacts were seen in 10/27 patients (37 %).

Radmanesh report on 242 patients (of a total of 3661 patients, 6.6 %) with neurological symptoms in New York, who were examined primarily with CT. 13 patients (4.5 %) had acute or subacute ischemic infarct and 11 patients (3.8 %) intracranial hemorrhages. The majority of patients had no specific changes, particularly no meningeal contrast enhancement [8].

The high prevalence of cases of cerebral ischemia occurring in association with COVID-19 is noteworthy. Case series from France [9], the USA [10], and Italy [11] show a significantly worse clinical neurological outcome and a greater mortality rate in patients with COVID-19 and cerebral ischemia compared to patients without
Fig. 1 Presumed central pontine myelinolysis in a patient with severe and prolonged COVID-19 course. Hyperintense central pontine lesion in T2w images. A with corresponding diffusion impairment B but without contrast enhancement C after contrast agent administration. While hospitalized, the patient showed no hyponatremia and no relevant hypernatremia but now requires dialysis. There were no laboratory findings prior to the patient being transferred to us. Lumbar puncture was not performed.

Table 1a Clinical and radiological information regarding the included patients in chronological order. Sex and age are not individually specified.

<table>
<thead>
<tr>
<th>#</th>
<th>site</th>
<th>severity of COVID-19</th>
<th>neurological symptoms, reason for imaging</th>
<th>modality</th>
<th>primary findings</th>
<th>secondary findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Kiel</td>
<td>moderate</td>
<td>confusion</td>
<td>CT</td>
<td>–</td>
<td>pronounced microangiopathic white matter damage, Old embolic infarcts</td>
</tr>
<tr>
<td>2</td>
<td>Kiel</td>
<td>moderate</td>
<td>confusion, fall</td>
<td>CT</td>
<td>–</td>
<td>minimal microangiopathic white matter damage</td>
</tr>
<tr>
<td>3</td>
<td>Kiel</td>
<td>mild</td>
<td>temporary loss of consciousness</td>
<td>CT</td>
<td>–</td>
<td>pronounced microangiopathic white matter damage, Old embolic infarcts</td>
</tr>
<tr>
<td>4</td>
<td>Lübeck</td>
<td>severe</td>
<td>Impaired consciousness</td>
<td>CT, CTA</td>
<td>–</td>
<td>residuals after AVM surgery</td>
</tr>
<tr>
<td>5</td>
<td>Kiel</td>
<td>moderate</td>
<td>confusion, fall</td>
<td>CT</td>
<td>–</td>
<td>minimal microangiopathic white matter damage</td>
</tr>
<tr>
<td>6</td>
<td>Kiel</td>
<td>mild</td>
<td>right paresthesia</td>
<td>MRI, CT</td>
<td>subacute embolic infarcts</td>
<td>arteriosclerosis of the intracranial vessels</td>
</tr>
<tr>
<td>7</td>
<td>Kiel</td>
<td>severe</td>
<td>Impaired consciousness</td>
<td>CT, MRI</td>
<td>subacute and acute infarcts, diffuse subarachnoid hemorrhage, cerebellar intracerebro-lateral hemorrhage, primarily central pontine myelinolysis</td>
<td>–</td>
</tr>
<tr>
<td>8</td>
<td>Kiel</td>
<td>moderate</td>
<td>headache</td>
<td>MRI</td>
<td>pansinusitis</td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>Lübeck</td>
<td>severe</td>
<td>Impaired consciousness</td>
<td>CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>10</td>
<td>Lübeck</td>
<td>mild</td>
<td>dizziness, sudden hearing loss</td>
<td>CT, MRI</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>Lübeck</td>
<td>severe</td>
<td>Impaired consciousness</td>
<td>CT</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>12</td>
<td>Kiel</td>
<td>moderate</td>
<td>hyposmia and hypogeusia</td>
<td>MRI</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
COVID-19 and cerebral ischemia. In addition, COVID-19 was identified as an independent risk factor for cerebral ischemia [12].

As in other collectives, the frequency of neurological symptoms (approx. 18 %) in our cohort is lower than that reported by Mao et al. One reason for this is that we only included patients with neurological symptoms resulting in cerebral imaging. Two patients in our cohort had cerebral ischemia (approx. 17 %) and one patient (approx. 8 %) had intracranial hemorrhages. However, most patients did not have any acute pathologies which corresponds with the literature.

Various damage mechanisms of the CNS have been discussed. 1) Direct neuroinvasion by SARS-CoV; 2) Secondary cerebral damage caused by ischemia and bleeding due to possible endothelial dysfunction and systemic hypercoagulability and possibly due to thromboses of the small cerebral veins caused by cerebral hemorrhages [13]. 3) Indirect damage due to cytokines and post-infection antibodies [14]. To date, it has not been possible to clearly define the damage pattern and the clarify which mechanisms are most prevalent and how frequently they occur. Neuropathological correlation studies are necessary to answer these questions and to identify a causality between the infection and damage patterns [15].

We present the first German case series from a minimally affected region. Our study includes COVID-19 patients with mild, moderate, and severe disease courses who underwent neuroro-
diological imaging and includes post-infection data and data regarding newly occurring neurological symptoms. In summary, these findings are currently still heterogeneous and nonspecific. Further long-term studies are needed to detect potential residual and late effects of COVID-19. In this regard, we initiated a population-based cohort study www.covidom.de.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


Table 1b Time of occurrence and outcome regarding neurological symptoms.

<table>
<thead>
<tr>
<th>#</th>
<th>neurological symptoms</th>
<th>start of neurological symptoms</th>
<th>outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>confusion with other symptoms</td>
<td></td>
<td>death</td>
</tr>
<tr>
<td>2</td>
<td>confusion with other symptoms</td>
<td></td>
<td>asymptomatic</td>
</tr>
<tr>
<td>3</td>
<td>temporary loss of consciousness</td>
<td>with other symptoms</td>
<td>asymptomatic</td>
</tr>
<tr>
<td>4</td>
<td>Impaired consciousness during hospitalization</td>
<td>asymptomatic</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>confusion with other symptoms</td>
<td></td>
<td>asymptomatic</td>
</tr>
<tr>
<td>6</td>
<td>right paresthesia weeks later</td>
<td></td>
<td>asymptomatic</td>
</tr>
<tr>
<td>7</td>
<td>Impaired consciousness during hospitalization</td>
<td>asymptomatic</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>headache with other symptoms</td>
<td></td>
<td>asymptomatic</td>
</tr>
<tr>
<td>9</td>
<td>Impaired consciousness during hospitalization</td>
<td>death</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>dizziness, sudden hearing loss weeks later</td>
<td>asymptomatic</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Impaired consciousness during hospitalization</td>
<td>death</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>hyposmia and hypogeusia with other symptoms</td>
<td>asymptomatic</td>
<td></td>
</tr>
</tbody>
</table>

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.